Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. - Wikidata - wikimedia - TriplyDB

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

http://www.wikidata.org/entity/Q36431370

about

Role of pregnane X receptor in chemotherapeutic treatment Polymers influencing transportability profile of drug Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems.P-glycoprotein and bioavailability-implication of polymorphism.Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.Novel formulations of taxanes: a review. Old wine in a new bottle?Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations.Improving cancer chemotherapy with modulators of ABC drug transporters.Pharmacokinetic variability of anticancer agents.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Role of efflux pumps and metabolising enzymes in drug delivery.A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier Natural and synthetic polymers as inhibitors of drug efflux pumps.The drug transporter-metabolism alliance: uncovering and defining the interplay.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.P-glycoprotein Inhibition for Optimal Drug Delivery.Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.Chemopreventive effects of aloe against genotoxicity induced by benzo[a]pyrene.Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.Spectrophotometric Studies on the Thermodynamics of the ds-DNA Interaction with Irinotecan for a Better Understanding of Anticancer Drug-DNA Interactions Preparation and Evaluation of Solid-Self-Emulsifying Drug Delivery System Containing Paclitaxel for Lymphatic Delivery

P2860

Q26827398-E3A15C6A-E3EA-4F85-A1ED-5FBF6AE18835 Q26862824-D0B466EA-4E06-4CE2-A79B-4E068B6F3E7E Q28345475-15385771-AEEE-4F78-ADEC-C90907616705 Q28364886-80236479-81DE-4DE8-8540-1E32CDB76D08 Q33214448-1C5E05DA-D124-43DB-8B42-30202E49BE11 Q33366351-D92E5D99-4A1B-4B9F-9982-8528218D90C4 Q33547006-BC75AAC6-D9A7-4388-B0D0-7A028FF56EA8 Q34093099-D2C08057-D57D-410D-9462-4AD72DE1B0D7 Q34303346-0C06F972-27D4-455A-AB54-A6E15F459AA7 Q34528991-014E4E9A-0E6B-47D8-9F43-9F525D5A41C6 Q34563540-DC8093A8-8A49-402C-AE6B-E2492821A437 Q34814991-F9E48FA9-CC9B-41CB-9E7F-F95BD602E5B5 Q35178040-19AF8DD7-19E2-4F8B-ADF1-287A6228871F Q35196297-B228D553-B2B2-4036-8AED-5F32F2AF79CD Q35691738-7A3959DE-E0D9-48C5-AE6A-C2830781223B Q36108251-ECA1EE8A-7E33-4C12-9AAA-29D0A1C8895D Q36146910-17B412ED-533E-4E7B-89C8-953C11684268 Q36271954-C0A93A81-8192-42D0-8A66-35E2B2A69FA5 Q36316872-3221F1F4-4FA6-4358-B109-0486B6C4844E Q36867354-DB9B037B-F68E-4974-8F46-2BA25ED9A0A3 Q36951710-7C071C26-9277-4233-B9F1-C0F6C12BC475 Q37485904-686FCA22-063E-4A9E-AACE-9549CDFAA432 Q37841631-BF478FD2-8CFF-4DC0-A937-2ECE6C7E5053 Q38082728-86BDB2E0-2A35-494C-B1C4-4CD47E76543F Q38136183-3FCB03C5-21E4-4E86-8AC0-9103C16E366E Q38167822-65EE93DC-1A42-46F0-BBF2-4CBF370FF290 Q39296280-1377889C-905A-4C20-87C0-8D99C884706C Q40036535-036EB3F3-22B1-4736-9DE6-779CF74EA5A5 Q40948116-CA3794E5-151A-4B39-A941-BC9A164BA900 Q41611878-8A237532-21DC-4C2D-A036-05A1DBF04774 Q41821858-0BBD8617-6791-4C9F-AF97-BD45A7AB7780 Q42436472-598A6591-C936-4CB2-8D1B-5150FC9B81F5 Q44027605-1CE80C9E-922F-4241-BFD4-1CCF0B0B7FCD Q44490316-5CD54B72-32CF-4172-A862-DCE0FF385B99 Q46304754-6ADA0D5C-F547-4BD9-B4EB-04BD0C1D0C3C Q46738108-DA3D0588-4833-4F58-BBD4-BF6DFAD091AF Q46954005-B964BAC8-5D5C-44D4-B8CB-A66A9AA537CD Q51919248-5ADAEB4A-62F6-49E5-8C28-A758A911CF64 Q59020811-B58AF980-1E9B-4793-9E44-81574A724606 Q59127370-DFBFA8E2-FC29-486E-B620-51926F6517C4

P2860

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

http://www.wikidata.org/entity/Q36431370

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh

1997年學術文章

@zh-hant

name

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@ast

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@en

type

label

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@ast

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@en

prefLabel

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@ast

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@en

P1433

Q36431370-57402057-73D8-42C3-A2D1-57337EF5B45A

P1476

Q36431370-B680460D-DA0D-4DA7-9E3E-4CBF1AF7C747

P2093

Q36431370-21AF3C32-3B05-4175-911D-380BAFAC082C

Q36431370-247A34E0-2284-47DB-AF17-6494D75768CA

Q36431370-26FE7DAE-3D8E-4A18-A540-2EDCF4F18506

Q36431370-52B5B3AB-29E7-4ACF-BD7F-B93E92AD6CFC

Q36431370-6C58B6F6-107C-4D45-9CD2-18746FDC89F0

Q36431370-88667C0E-4B23-4319-AF0D-20EF91913380

Q36431370-AD86D7DE-3368-4363-870E-38802E2AD9A3

P2860

Q36431370-08F172C2-967F-43B9-9BA4-AFC00FF6DE08

Q36431370-183A8365-EA07-4DD6-9765-E6719254B9D4

Q36431370-28726D22-8B03-4DB8-8BE4-DB21A60EABAD

Q36431370-4FCE8B70-DC19-41A1-B8CA-A388CDB68521

Q36431370-9F870823-00A9-42C8-9CC4-0A0EA334797B

Q36431370-A373E949-F07D-405E-A55E-24D18542F789

Q36431370-B63CC1FA-7596-4348-886D-D4DD935FF992

Q36431370-C2D44E50-51BF-44E2-BA9A-6824BB8D707B

Q36431370-C76BA314-C8F8-455A-9DA2-32AE57A8AA87

Q36431370-CDF782A6-166B-44DC-9E23-368873463E3E

P2888

Q36431370-236FE426-0E7C-4F13-9BA7-985283BFC892

P304

Q36431370-A38B308E-4B8E-4D70-96DC-C14D5C819B30

P31

Q36431370-ABDB271A-DC2A-4335-A3A7-24812F48786C

P356

Q36431370-DFA17BB6-B42C-4840-8F13-5C665C96544A

P407

Q36431370-0DDB4064-3512-4FC5-A649-6EE0FCB02912

P433

Q36431370-39EBEF18-EC70-45EB-88A1-9B834A7C02FC

P478

Q36431370-07ECB764-DDD5-4195-90B9-D5C365BF3CFC

P577

Q36431370-30DC4D67-B020-4717-9B1D-772BC6ED5BB0

P5875

Q36431370-C1794967-E457-45B4-BBF5-79C46EDEA2EB

P6179

Q36431370-1EAB0F17-57C9-4D0C-A53E-F26000BFD491

P698

Q36431370-D31DDB8E-5397-4875-9F93-F6896088C4E4

P932

Q36431370-B40F119F-1512-4C7C-A7FE-3AFD48C0A440

P356

P1433

British Journal of Cancer

P1476

Enhanced oral bioavailability ...... coprotein blocker SDZ PSC 833.

@en

P2093

A H Schinkel

http://www.w3.org/2001/XMLSchema#string

A Sparreboom

http://www.w3.org/2001/XMLSchema#string

J H Beijnen

http://www.w3.org/2001/XMLSchema#string

J van Asperen

http://www.w3.org/2001/XMLSchema#string

O van Tellingen

http://www.w3.org/2001/XMLSchema#string

P Borst

http://www.w3.org/2001/XMLSchema#string

W J Nooijen

http://www.w3.org/2001/XMLSchema#string

P2860

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Paclitaxel (taxol)

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.

Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas.

The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues

Taxanes: a new class of antitumor agents.

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Pharmacological considerations in the modulation of multidrug resistance.

SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.

P2888

P304

1181-1183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1997.530

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13865031

http://www.w3.org/2001/XMLSchema#string

P6179

1024117195

http://www.w3.org/2001/XMLSchema#string

P698

9365166

http://www.w3.org/2001/XMLSchema#string

P932

2228133

http://www.w3.org/2001/XMLSchema#string